Internal Medicine, Hematology & Oncology · Torrance, CA
NPI
1801968334
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3285 Skypark Dr
Torrance, CA, 90505
Phone (310) 750-3300
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
195,635 services
Medicare patients, 2024
497
Average age 77
Drug cost, 2024
$6.2M
1,344 prescriptions
Company payments, 2025
$577
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas E Lowe was code J1453 (injection, fosaprepitant, 1 mg), 22,360 times for 22 patients. In total Thomas E Lowe billed 195,635 services in 113 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-12-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 22,360 | 22 | $0.11 | $2,503 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 21,700 | 11 | $0.06 | $1,195 |
| J1642 Injection, heparin sodium, (heparin lock flush), per 10 units | Office | 16,701 | 26 | $0.01 | $210 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 2,330 | 34 | $0.25 | $592 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,244 | 29 | $0.09 | $203 |
| 85025 Blood Count | Office | 1,530 | 348 | $7.59 | $12K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,310 | 13 | $3.54 | $4,641 |
| 96367 Intravenous Infusion, Hydration | Office | 752 | 36 | $25.28 | $19K |
| J9190 Injection, fluorouracil, 500 mg | Office | 720 | 13 | $2.32 | $1,670 |
| 99213 Office E&M - Established | Office | 600 | 359 | $68.87 | $41K |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 398 | 50 | $68.60 | $27K |
| 96413 Chemotherapy Administration | Office | 376 | 51 | $115.05 | $43K |
| 99215 Office E&M - Established | Office | 340 | 101 | $150.08 | $51K |
| 96401 Chemotherapy Administration | Office | 311 | 18 | $63.60 | $20K |
| 99214 Office E&M - Established | Office | 308 | 141 | $99.57 | $31K |
By year: 2022 $2.8M for 201,016 services; 2023 $3.2M for 213,415 services; 2024 $3.2M for 195,635 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,530 | 348 | $7.59 | $12K |
| 81002 Clinical Chemistry | 39 | 13 | $3.41 | $133 |
| 82565 Clinical Chemistry | 29 | 17 | $5.02 | $146 |
| 36415 Venipuncture Blood Collection | 16 | 11 | $8.65 | $138 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas E Lowe prescribed most often to Medicare patients was Anastrozole, with 89 prescriptions and refills. In total Thomas E Lowe wrote 1,344 Medicare prescriptions that cost $6.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 89 | 264 | 25 | $2,206 |
| Hydroxyurea Generic | 71 | 191 | 20 | $1,652 |
| Dexamethasone Generic | 61 | 101 | 33 | $1,472 |
| Tamoxifen Citrate Generic | 59 | 153 | 16 | $1,621 |
| Eliquis Apixaban | 56 | 98 | 15 | $55K |
| Lenalidomide Generic | 51 | 51 | Under 11 | $607K |
| Prochlorperazine Maleate Generic | 50 | 50 | 35 | $975 |
| Revlimid Lenalidomide | 50 | 50 | Under 11 | $755K |
| Acyclovir Generic | 46 | 134 | 17 | $1,865 |
| Ondansetron Odt Ondansetron | 37 | 37 | 29 | $555 |
| Imbruvica Ibrutinib | 35 | 35 | Under 11 | $540K |
| Levothyroxine Sodium Generic | 34 | 70 | Under 11 | $417 |
| Prednisone Generic | 33 | 64 | 17 | $184 |
| Pomalyst Pomalidomide | 30 | 30 | Under 11 | $611K |
| Xtandi Enzalutamide | 29 | 29 | Under 11 | $406K |
Brand drugs: - claims; generic drugs: 887 claims; opioid claims: 33.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas E Lowe $577 ($577 in general payments such as food, travel and fees) from 11 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $160.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 7 | $160 |
| Genentech USA, Inc. ROG.SW | 4 | $101 |
| Array Biopharma Inc PFE | 3 | $80.11 |
| Puma Biotechnology, Inc. PBYI | 3 | $60.47 |
| Janssen Biotech, Inc. JNJ | 2 | $49.87 |
| Celgene Corporation BMY | 2 | $32.34 |
| Aimmune Therapeutics, Inc. | 1 | $30.77 |
| Merck Sharp & Dohme LLC MRK | 1 | $27.06 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $20.41 |
| Apellis Pharmaceuticals, Inc. APLS | 1 | $14.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.